Impact of Oral Versatile Antioxidants on Glaucoma Progression
NCT ID: NCT01544192
Last Updated: 2012-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
60 participants
INTERVENTIONAL
2008-04-30
2012-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Methods: In this non-randomized control trial, 120 eyes of 60 patients with glaucoma were enrolled into the study and divided into 4 groups, each consisting of 30 eyes. Unlike the controls, patients in the 3 antioxidant groups received α-tocopherol, Gingko Biloba and a strong antioxidant formula for 3 months. Central vision field and MD, PSD and OCT as well as thickness of retinal nerve fiber layer, ganglion cell counts and c/d ratios were recorded. The data were compared statistically.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Ginkgo Biloba Capsule on Visual Function of Primary Open-angle Glaucoma With Blood Stasis Syndrome
NCT04334564
To Evaluate the Effect of Ginkgo Biloba Extract on Optic Nerve Head Perfusion Examined Using OCTA
NCT04846179
The Effects of an Antioxidant Formulation on Ocular Blood Flow
NCT01930487
Metformin as a Neuroprotective Therapy for Glaucoma
NCT05426044
The Antioxidant Effect of Routine Vascular Therapy for Normal Tension Glaucoma Patients
NCT00465348
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
No statistically significant difference was present between s-GCC and i-GCC levels of groups (p\>0.05). A high statistically significant difference was found between m-GCC levels of groups (p\<0.01). While highly 201 significant and significant difference were present between m-GCC level of the Vit E Group and m-GCC levels of AOF and Control Groups, respectively, (p\<0.01, p\<0.05), m-GCC level of the Group GB was significantly higher than that of Group AOF (p\<0.05). No statistically significant difference was observed between m-GCC levels of other groups (p\>0.05).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
retinal nerve fiber thickness
Gingko Biloba
2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)
α-tocopherol
2x300 mg α-tocopherol
Placebo
control group did not receive oral neuroprotective agent
Antioxidant formula
2x1 tablet AOF
Mean Deviation
Gingko Biloba
2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)
α-tocopherol
2x300 mg α-tocopherol
Placebo
control group did not receive oral neuroprotective agent
Antioxidant formula
2x1 tablet AOF
Pattern Standard Deviation
Gingko Biloba
2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)
α-tocopherol
2x300 mg α-tocopherol
Placebo
control group did not receive oral neuroprotective agent
Antioxidant formula
2x1 tablet AOF
ganglion cell count
Gingko Biloba
2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)
α-tocopherol
2x300 mg α-tocopherol
Placebo
control group did not receive oral neuroprotective agent
Antioxidant formula
2x1 tablet AOF
c/d ratios
Gingko Biloba
2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)
α-tocopherol
2x300 mg α-tocopherol
Placebo
control group did not receive oral neuroprotective agent
Antioxidant formula
2x1 tablet AOF
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gingko Biloba
2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)
α-tocopherol
2x300 mg α-tocopherol
Placebo
control group did not receive oral neuroprotective agent
Antioxidant formula
2x1 tablet AOF
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Previous glaucoma surgeries
* Antioxidant usage
18 Years
67 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bagcilar Training and Research Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kaya N Engin, MD,PhD
Role: STUDY_DIRECTOR
Bagcilar TRH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bakırköy Şadi Konuk Training and Research Hospital
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BEAH-Ophthalmol-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.